



#### FY24 HALF YEAR RESULTS PRESENTATION

# ECS Botanics Holdings Ltd

A large-scale organic cultivator and manufacturer of GMP medicinal cannabis products

ASX : ECS

6 March 2024



## H1 FY24 Financial Highlights


#### **Record revenue and profitable**


- Record Revenue up 70% on previous corresponding period (PCP)
- EBITDA of \$1.9m, up from \$1.0 m loss in PCP
- Profitable operations, with NPAT of \$1.2m (H1 FY23: loss of \$1.4m)
- ✓ Positive operating cash flow for the half of \$0.6m, whilst continuing to invest in business expansion

### Capital raise announced in Feb 2024 to fund further

- expansion to meet demand
- ✓ \$4.0m Placement completed at \$0.022 per share, undertaken by Bell Potter Securities
- ✓ Funded to significantly increase production, expand exports and introduce own B2C brand

#### Total Revenue vs PCP in \$ millions







## H1 FY24 Financial Results: Balance Sheet & Cash flow

#### Strong balance sheet strengthened with capital raise

- Significant investment in the establishment of 25,000m2 (60% increase) new outdoor fields including irrigation and processing facilities
- Cash balance of \$2.6 million
- NAB facility of \$2 million which remains undrawn
- Additional \$4 million raised via placement in February 2024 (post-balance sheet)

#### Generating positive operating cash flows

- Receipts from customers up 68% on PCP
- Positive net operating cash flow for the half of \$0.6m

BALANCE SHEET	31-Dec-23	30-Jun-23
Cash	2.6	2.5
Total Assets	30.5	26.1
Current financial liabilities	(6.3)	(3.7)
Total liabilities	(7.0)	(3.9)
Net assets	23.5	22.2

CASH FLOW	31-Dec-23	30-Jun-23
Receipts from customers	10.5	6.2
Net cash from operating activities	0.6	0.4
Net cash from investing activities	(1.1)	(0.04)
Net cash from financing activities	0.5	0.3
Net increase in cash and cash equivalents	0.04	0.67
Cash and cash equivalents at the end of the year	2.6	2.5



## H1 FY24 Operational Highlights

#### Growing order book

- Major long-term Australian and International supply agreements executed bringing total to ~\$60m over 18 months
- Trial shipment to German partner Ilios Santé completed
- Strong demand for ECS' latest product launch of white label Pastilles (gummies)
- ✓ Obtained Organic certification (in conversion)

#### Growing capacity to meet demand

- ✓ Outdoor cultivation area expanded by 60%. ODC permit to produce up to 13 tonnes
- R&D project demonstrates value in investing in additional heating and lighting in four Protective Cropping Enclosures (PCE's) allowing ECS to produce 4 cycles vs 2 annually
- ✓ In February 2024 SunPharma were GMP certified to extract biomass enabling ECS to substantially reduce cost of oils





## The ECS Advantage

Cost "globally competitive"	<ul> <li>Fit for purpose Operational Infrastructure e.g. PCE \$500/m<sup>2</sup> vs Greenhouse \$2000/m<sup>2</sup></li> <li>Optimum production controllers e.g. IOT controllers (\$10K) vs Siemens BMS (\$150K)</li> <li>Free sunshine vs electricity</li> <li>Outdoor vs Indoor for biomass (oils)</li> <li>Scale from B2B strategy</li> <li>Fiscal discipline across the organisation</li> </ul>	ASX Listed Competitor Financial H1 FY24 Performance (in A\$ million) \$15.4 \$11.7 \$8.5 \$4.9 \$1.2
Quality "meeting global standards"	<ul> <li>euGMP post-harvest processing</li> <li>Investment in mechanisation</li> <li>International in-house expertise in Cultivation, Manufacturing, Genetics and Quality</li> </ul>	ECS Company A Company B Company C -\$12.3
ESG "part of our DNA"	<ul> <li>Organic, Regenerative, Solar</li> <li>RAP discounted military veterans' products</li> <li>Community engagement</li> <li>Diversity in culture, gender and age</li> </ul>	-\$14.3 -\$16.6 Revenue Profit/ Loss



## Medical Cannabis A Large and Growing Export Market.

#### Germany population 80 million

- April 2024 new laws planned to remove Cannabis from banned substance under narcotics which is anticipated to:
- Increase accessibility and simpler prescription process
- More efficient importing and less reporting
- Greater inventory holdings
- More social acceptance
- ECS is working with Ilios Santé to leverage increase in Medicinal Cannabis demand

#### Poland population 38 million

- Although legal for 4 years market remains small due to very high regulatory requirements
- ECS registration has taken 3 years being finalised with first shipment anticipated in Q4
- Koyi contracted for \$4 million

#### **United Kingdom population 67 million**

 ECS has \$9.3 million supply agreement with Rokshaw, the largest distributers of Medical Cannabis in the UK





## Medical Cannabis A Large and Growing Export Market.

#### **USA population 332 million**

- In January 2024 the Dept of Health and Human Services recommended rescheduling Cannabis from Schedule 1 to Schedule 3 to the Drug Enforcement Administration
- If adopted the US Cannabis market will unlock investment and more universal access
- Expected to have global implications including in company valuations

### Australia population 26 million

- Market size estimated to be \$400 -500 million
- Rapid growth in demand resulted in substantial increase in flower brands currently on sale
- Flower market now 70% of sales, is growing rapidly due to increased number of clinics
- Pressure being applied to TGA to better regulate imports and quality





## Strategy for Increasing Growth and Profitability in EU and Australia

Expansion "to meet growing demand"	<ul> <li>Increase production by December 2025 to licensed capacity of 13.7 tonnes per annum</li> <li>Construct and fit-out 9 new PCE's</li> <li>Flatten labour with year-round grow with heating and lighting to further increase production</li> <li>Sun Pharma extraction price advantage</li> <li>Vertical integration to capture more revenue and margin</li> </ul>
Quality "meeting global standards"	<ul> <li>New genetics to meet patient preferences and provide consistent good quality flower</li> <li>Organic product providing key differentiation especially in Germany</li> <li>Terpenes returned to extracts to provide full spectrum oils</li> </ul>
IP "building differentiation"	<ul> <li>VESIsorb<sup>®</sup> delivery technology increases Cannabidiol level in blood plasma x4 and is absorbed into bloodstream 3x faster</li> <li>Add additional product lines gummies, topicals and water-soluble drops</li> <li>Organic flower and Oils</li> <li>Building out AVANI own brand</li> <li>New Genetics being commercialised as well as ongoing development in new Genetics facility to expand customer base</li> </ul>



#### Sun Pharma extractor installed





## **Strategic Roadmap Summary**

Delivering on a Clear Strategy to Drive Value.

#### Developing Capability and Confidence

- ✓ Established in 2018
- ✓ ODC Licenced in 2019
- ✓ TGA Licenced in 2020
- ✓ First Cultivation 2020

## $2018-2020 \rightarrow 2021-2023$

#### Focused, Expanding and Growing Revenue

- ✓ Acquired Murray Meds
- ✓ Exporting to NZ and UK
- ✓ Focussed Victoria operations
- ✓ Organic certification
- ✓ Added 12 Greenhouses
- ✓ Positive EBITDA
- ✓ >A\$50m in sales contracts
- ✓ Established an expert team
- $\checkmark$  >4 tonnes production

## 2024-2026

#### Drive Profitability, Innovation and Expansion

- Add 9 more greenhouses and light/heating for all year growing capability
- Scale to >13 tonnes production in line with licensed capacity
- Scale exports into existing and new markets to be >30% of Revenue
- Launch and build Avani B2C brand
- Leverage IP with VESIsorb<sup>®</sup> and • Genetics through Avani brand
- Vertically integrated manufacturer of **Oils, Capsule, Vapes and Pastilles**
- Largest Australian exporter of flower

## 2027-2029

#### Top 2 in Medicinal Cannabis in Australia and largest exporter

- Exporting to Asia and North America
- Exports >60% of Revenues
- Avani recognised as the leading brand in multiple markets
- ARTG listing for Avani Rapid medicinal cannabis capsules
- Carbon Neutral
- Organic Investment in expansion
- Most profitable Australian Cannabis Company

ECS BOTANICS HOLDINGS LTD



## Questions



## **Disclaimer**

This presentation has been prepared by ECS Botanics Holdings Limited ("Company").

This presentation, dated 6 March 2024, should be read in conjunction with, and subject to, all information previously released to the market by Company. This presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in the Company.

In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. The information in this presentation is general only and does not constitute personal investment advice. Investors should assess their own personal financial circumstances, conduct their own investigations and consider seeking professional advice before making any investment decision. All securities involve risks which include (among others) the risk of adverse or unanticipated market, financial or political developments.

This presentation is for general information purposes only. Neither this presentation nor the information contained in it constitutes an offer, invitation, solicitation or

recommendation in relation to the purchase or sales of shares or other securities in any jurisdiction.

Certain statements in this presentation constitute forward looking statements which are based on information available to the Company as at the date of this presentation. Such forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements.

While reasonable care has been taken in relation to the preparation of this presentation, none of the Company, its related entities, or their respective directors, officers, employees, contractors or agents accepts responsibility for any loss or damage resulting from the use of or reliance on this presentation by any person and, to the maximum extent permitted by law, all such loss and damage is expressly disclaimed.

No representation or warranty, express or implied, is made or given by or on behalf of the Company, its related entities, or their respective directors, officers, employees,

contractors or agents about the accuracy, completeness or fairness of any information or opinions contained in this presentation. No responsibility for any errors or omissions from this presentation arising out of negligence or otherwise are accepted.

Any opinions contained in this presentation reflect the Company's position at the date of this presentation based on information then known to the Company and are subject to change.

This presentation is not a prospectus, investment statement or disclosure document, or an offer of shares for subscription, or sale, in any jurisdiction. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The Company has not, and will not, register the offer of any shares under the *US Securities Act of 1933*. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed.

All intellectual property, proprietary and other rights and interests in this presentation are owned by the Company.